A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

被引：7

作者：

Akaza, Hideyuki ^{[1
]}

Uemura, Hirotsugu ^{[2
]}

Tsukamoto, Taiji ^{[3
]}

Ozono, Seiichiro ^{[4
]}

Ogawa, Osamu ^{[5
]}

Sakai, Hideki ^{[6
]}

Oya, Mototsugu ^{[7
]}

Namiki, Mikio ^{[8
]}

Fukasawa, Satoshi ^{[9
]}

Yamaguchi, Akito ^{[10
]}

Uemura, Hiroji ^{[11
]}

Ohashi, Yasuo ^{[12
]}

Maeda, Hideki ^{[13
]}

Saito, Atsushi ^{[13
]}

Takeda, Kentaro ^{[13
]}

Naito, Seiji ^{[10
]}

机构：

[1] Univ Tokyo, Strateg Invest Comprehens Canc Network, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan

[2] Kinki Univ, Dept Urol, Fac Med, 377-2 Ono Higashi, Osakasayama 5898511, Japan

[3] Sapporo Med Univ, Dept Urol, Sch Med, S1 W17 Chuo Ku, Sapporo, Hokkaido 0608556, Japan

[4] Hamamatsu Univ Sch Med, Dept Urol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan

[5] Kyoto Univ, Dept Urol, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan

[6] Nagasaki Univ, Dept Urol, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan

[7] Keio Univ, Dept Urol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

[8] Kanazawa Univ, Dept Integrat Canc Therapy & Urol, Grad Sch Med Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan

[9] Chiba Canc Ctr, Dept Urol, Chuo Ku, 666-2 Nitona Cho, Chiba 2608717, Japan

[10] Harasanshin Hosp, Div Urol, Hakata Ku, 1-8 Taihakumachi, Fukuoka 8120033, Japan

[11] Yokohama City Univ, Dept Urol & Renal Transplantat, Med Ctr, Minami Ku, 4-57 Urafune, Yokohama, Kanagawa 2320024, Japan

[12] Chuo Univ, Dept Integrated Sci & Engn Sustainable Soc, Bunkyo Ku, 1-13-27 Kasuga, Tokyo 1128551, Japan

[13] Astellas Pharma Inc, Chuo Ku, 2-5-1 Nihonbashi Honcho, Tokyo 1038411, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 21卷 / 04期

关键词：

Androgen receptor inhibitor; Enzalutamide; Metastatic castration-resistant prostate cancer; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; CLINICAL ACTIVITY; DOCETAXEL; THERAPY; TRIAL; PREDNISOLONE; MITOXANTRONE; ANTIANDROGEN;

D O I：

10.1007/s10147-016-0952-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Trial registration: ClinicalTrials.gov NCT01284920.

引用

页码：773 / 782

页数：10

共 50 条

[21] ENZALUTAMIDE FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
Ha, Y-S
Goodin, S.
DiPaola, R. S.
Kim, I. Y.
DRUGS OF TODAY, 2013, 49 (01) : 7 - 13
[22] Enzalutamide: A Review in Castration-Resistant Prostate Cancer
Scott, Lesley J.
DRUGS, 2018, 78 (18) : 1913 - 1924
[23] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
La, Jennifer
Wang, Lin
Corrigan, June K.
Lang, Deborah
Lee, Michelle H.
Do, Nhan V.
Brophy, Mary T.
Paller, Channing J.
Fillmore, Nathanael R.
JAMA NETWORK OPEN, 2024, 7 (08)
[24] Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
Serritella, Anthony, V
Shevrin, Daniel
Heath, Elisabeth, I
Wade, James L.
Martinez, Elia
Anderson, Amanda
Schonhoft, Joseph
Chu, Yen-Lin
Karrison, Theodore
Stadler, Walter M.
Szmulewitz, Russell Z.
CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1549 - 1559
[25] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
Rexer, H.
Graefen, M.
UROLOGE, 2017, 56 (11): : 1468 - 1470
[26] Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
Yu, Evan Y.
Wilding, George
Posadas, Edwin
Gross, Mitchell
Culine, Stephane
Massard, Christophe
Morris, Michael J.
Hudes, Gary
Calabro, Fabio
Cheng, Shinta
Trudel, Geralyn C.
Paliwal, Prashni
Sternberg, Cora N.
CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7421 - 7428
[27] A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
Courtney, Kevin D.
Manola, Judith B.
Elfiky, Aymen A.
Ross, Robert
Oh, William K.
Yap, Jeffrey T.
Van den Abbeele, Annick D.
Ryan, Christopher W.
Beer, Tomasz M.
Loda, Massimo
Priolo, Carmen
Kantoff, Philip
Taplin, Mary-Ellen
CLINICAL GENITOURINARY CANCER, 2015, 13 (02) : 113 - 123
[28] A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).
Pan, Chong-xian
Lara, Primo
Evans, Christopher P.
Parikh, Mamta
White, Ralph de Vere
Dall'era, Marc
Liu, Chengfei
Robles, Daniel
Gao, Allen
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[29] Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
Graff, Julie Nicole
Cheng, Heather H.
Vuky, Jacqueline
Alumkal, Joshi J.
Kreitner, Dustin
Petreaca, Delia
Grivas, Petros
Schweizer, Michael Thomas
Higano, Celestia S.
Chen, Yiyi
Yu, Evan Y.
Beer, Tomasz M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[30] Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Matsubara, Nobuaki
Nagamori, Satsohi
Wakumoto, Yoshiaki
Uemura, Hirotsugu
Kimura, Go
Yokomizo, Akira
Kikukawa, Hiroaki
Mizokami, Atsushi
Kosaka, Takeo
Masumori, Naoya
Kawasaki, Yoshihide
Yonese, Junji
Nasu, Yasutomo
Fukasawa, Satoshi
Sugiyama, Takayuki
Kinuya, Seigo
Hosono, Makoto
Yamaguchi, Iku
Tsutsui, Hirokazu
Uemura, Hiroji
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (01) : 173 - 180

← 1 2 3 4 5 →